Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

406 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831.
Perez EA, Romond EH, Suman VJ, Jeong JH, Sledge G, Geyer CE Jr, Martino S, Rastogi P, Gralow J, Swain SM, Winer EP, Colon-Otero G, Davidson NE, Mamounas E, Zujewski JA, Wolmark N. Perez EA, et al. Among authors: davidson ne. J Clin Oncol. 2014 Nov 20;32(33):3744-52. doi: 10.1200/JCO.2014.55.5730. Epub 2014 Oct 20. J Clin Oncol. 2014. PMID: 25332249 Free PMC article. Clinical Trial.
Predictive factors for peripheral-blood progenitor-cell collections using a single large-volume leukapheresis after cyclophosphamide and granulocyte-macrophage colony-stimulating factor mobilization.
Passos-Coelho JL, Braine HG, Davis JM, Huelskamp AM, Schepers KG, Ohly K, Clarke B, Wright SK, Noga SJ, Davidson NE, et al. Passos-Coelho JL, et al. Among authors: davidson ne. J Clin Oncol. 1995 Mar;13(3):705-14. doi: 10.1200/JCO.1995.13.3.705. J Clin Oncol. 1995. PMID: 7533827 Clinical Trial.
Similar breast cancer cell contamination of single-day peripheral-blood progenitor-cell collections obtained after priming with hematopoietic growth factor alone or after cyclophosphamide followed by growth factor.
Passos-Coelho JL, Ross AA, Kahn DJ, Moss TJ, Davis JM, Huelskamp AM, Noga SJ, Davidson NE, Kennedy MJ. Passos-Coelho JL, et al. Among authors: davidson ne. J Clin Oncol. 1996 Sep;14(9):2569-75. doi: 10.1200/JCO.1996.14.9.2569. J Clin Oncol. 1996. PMID: 8823337
Primary systemic therapy in operable breast cancer.
Wolff AC, Davidson NE. Wolff AC, et al. Among authors: davidson ne. J Clin Oncol. 2000 Apr;18(7):1558-69. doi: 10.1200/JCO.2000.18.7.1558. J Clin Oncol. 2000. PMID: 10735905 Review.
NCCN Practice Guidelines for Breast Cancer.
Carlson RW, Anderson BO, Bensinger W, Cox CE, Davidson NE, Edge SB, Farrar WB, Goldstein LJ, Gradishar WJ, Lichter AS, McCormick B, Nabell LM, Reed EC, Silver SM, Smith ML, Somlo G, Theriault R, Ward JH, Winer EP, Wolff A; National Comprehensive Cancer Network. Carlson RW, et al. Among authors: davidson ne. Oncology (Williston Park). 2000 Nov;14(11A):33-49. Oncology (Williston Park). 2000. PMID: 11195418
Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741.
Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ, Davidson NE, Martino S, Livingston R, Ingle JN, Perez EA, Carpenter J, Hurd D, Holland JF, Smith BL, Sartor CI, Leung EH, Abrams J, Schilsky RL, Muss HB, Norton L. Citron ML, et al. Among authors: davidson ne. J Clin Oncol. 2003 Apr 15;21(8):1431-9. doi: 10.1200/JCO.2003.09.081. Epub 2003 Feb 13. J Clin Oncol. 2003. PMID: 12668651 Clinical Trial.
406 results